New hope for rare cancers: first human trial of ANS03 begins
NCT ID NCT06716138
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called ANS03 in adults with advanced solid tumors that have specific gene changes (ROS1 or NTRK). The main goals are to check safety and find the right dose. About 96 participants will receive the drug, and doctors will monitor side effects and any tumor shrinkage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS HARBORING A ROS1 OR NTRK ALTERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10022, United States
-
Research Site
RECRUITINGFuzhou, Fujian, China
-
Research Site
RECRUITINGGuangzhou, Guangdong, China
-
Research Site
RECRUITINGShanghai, Shanghai Municipality, China
-
Research Site
RECRUITINGChengdu, Sichuan, China